<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Amplification or duplication of the AML1 gene at chromosome band 21q22 was detected by FISH using a locus-specific probe in three out of 171 unselected patients with therapy-related <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (1.7%) </plain></SENT>
<SENT sid="1" pm="."><plain>In two patients AML1 signals were located tandemly on derivative chromosomes, in one patient on a dic(9;21) and in the the other patient on a derivative chromosome 18 made up of interchanging layers of material from chromosomes 9, 14, 18, and 21 </plain></SENT>
<SENT sid="2" pm="."><plain>In the third patient three single supernumerary copies of AML1 were located on derivatives of chromosomes 19 and 21 </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three patients were older, had previously received therapy with <z:chebi fb="0" ids="22333">alkylating agents</z:chebi> without <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi>, had complex karyotypes including abnormalities of chromosomes 5 or 7, and presented acquired point mutations of the TP53 gene </plain></SENT>
<SENT sid="4" pm="."><plain>No point mutations of the AML1 gene were observed </plain></SENT>
<SENT sid="5" pm="."><plain>The results support a pivotal role of impaired TP53 function in the development of gene amplification or duplication in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>